Mytheresa upgraded by UBS with a new price target
$MYTE
Catalog/Specialty Distribution
Consumer Discretionary
UBS upgraded Mytheresa from Neutral to Buy and set a new price target of $19.00 from $30.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/14/2023 | $19.00 → $4.00 | Buy → Hold | Jefferies |
| 4/20/2023 | $7.00 | Buy → Hold | Societe Generale |
| 4/19/2023 | $7.00 | Overweight → Neutral | JP Morgan |
| 3/16/2023 | $13.00 → $7.00 | Outperform → Market Perform | TD Cowen |
| 4/12/2022 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/24/2022 | $30.00 → $19.00 | Neutral → Buy | UBS |
| 2/17/2022 | $35.00 → $27.00 | Outperform | Credit Suisse |
| 1/18/2022 | $25.00 | Hold → Buy | Societe Generale |
Strong Net Sales Growth in Q1 FY25 of 8% compared to Q1 FY24 Significant increase of Average Order Value (AOV) by 9% to a new record of €720 LTM in Q1 FY25 Double-digit US Market Growth with +14% in Q1 FY25 vs. Q1 FY24 and Net Sales share of the US further expanding to 20% Exceptional Customer Economics with strong increase in average GMV per top customers by +16.7% in Q1 FY25 Gross Margin Improvement of 150bps to 43.9% in Q1 FY25 as compared to Q1 FY24 Improved Profitability by 200bps at adjusted EBITDA margin level of 1.4% in Q1 FY25 as compared to -0.6% in the prior year period Transformational opportunity with the announced acquisition of YOOX NET-A-PORTER ("YNAP") to
MYT Netherlands Parent B.V. (NYSE:MYTE) ("Mytheresa") today announced the date for the release of its first quarter fiscal year 2025 ended September 30, 2024 financial results. First Quarter Fiscal Year 2025 Earnings Call and Webcast Mytheresa will release first quarter fiscal year 2025 financial results before the U.S. market open on November 19, 2024. A conference call to discuss its results will follow at 8:00am Eastern Time that same day. Those wishing to participate via webcast should access the call through Mytheresa's Investor Relations website at https://investors.mytheresa.com. Those wishing to participate via the telephone may dial in at +1 (800) 715-9871 (USA). The participant
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR 7 OCTOBER 2024 Richemont will sell YNAP to Mytheresa with a cash position of €555m and no financial debt, subject to customary closing adjustments Mytheresa to issue shares to Richemont representing 33% of Mytheresa's fully diluted share capital Richemont to provide a €100m revolving credit facility to YNAP Closing of transaction expected in H1 2025, subject to customary conditions, including regulatory approvals Transaction creates multi-brand digital group of significant scale, global reach as well as exceptional customer centricity Today, Mytheresa (NYSE:MYTE) and Richemont (SWX:CFR) announce that they have entered into binding agree
Jefferies downgraded Mytheresa from Buy to Hold and set a new price target of $4.00 from $19.00 previously
Societe Generale downgraded Mytheresa from Buy to Hold and set a new price target of $7.00
JP Morgan downgraded Mytheresa from Overweight to Neutral and set a new price target of $7.00
6-K/A - MYT Netherlands Parent B.V. (0001831907) (Filer)
6-K - MYT Netherlands Parent B.V. (0001831907) (Filer)
6-K/A - MYT Netherlands Parent B.V. (0001831907) (Filer)
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da
Strong Net Sales Growth in Q1 FY25 of 8% compared to Q1 FY24 Significant increase of Average Order Value (AOV) by 9% to a new record of €720 LTM in Q1 FY25 Double-digit US Market Growth with +14% in Q1 FY25 vs. Q1 FY24 and Net Sales share of the US further expanding to 20% Exceptional Customer Economics with strong increase in average GMV per top customers by +16.7% in Q1 FY25 Gross Margin Improvement of 150bps to 43.9% in Q1 FY25 as compared to Q1 FY24 Improved Profitability by 200bps at adjusted EBITDA margin level of 1.4% in Q1 FY25 as compared to -0.6% in the prior year period Transformational opportunity with the announced acquisition of YOOX NET-A-PORTER ("YNAP") to
MYT Netherlands Parent B.V. (NYSE:MYTE) ("Mytheresa") today announced the date for the release of its first quarter fiscal year 2025 ended September 30, 2024 financial results. First Quarter Fiscal Year 2025 Earnings Call and Webcast Mytheresa will release first quarter fiscal year 2025 financial results before the U.S. market open on November 19, 2024. A conference call to discuss its results will follow at 8:00am Eastern Time that same day. Those wishing to participate via webcast should access the call through Mytheresa's Investor Relations website at https://investors.mytheresa.com. Those wishing to participate via the telephone may dial in at +1 (800) 715-9871 (USA). The participant
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR 7 OCTOBER 2024 Richemont will sell YNAP to Mytheresa with a cash position of €555m and no financial debt, subject to customary closing adjustments Mytheresa to issue shares to Richemont representing 33% of Mytheresa's fully diluted share capital Richemont to provide a €100m revolving credit facility to YNAP Closing of transaction expected in H1 2025, subject to customary conditions, including regulatory approvals Transaction creates multi-brand digital group of significant scale, global reach as well as exceptional customer centricity Today, Mytheresa (NYSE:MYTE) and Richemont (SWX:CFR) announce that they have entered into binding agree